Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

The global Cell and Gene Therapy Market is valued at $20.5 billion in 2024 and is projected to reach a value of $128.8 ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...